Bank of New York Mellon’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Bank of New York Mellon’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-149,996	Closed	-$16.1M	–	4502
2023 Q1	$16.1M	Sell	149,996 -1,206	-0.8%	-$139K	﹤0.01%	1665
2022 Q4	$16.6M	Buy	151,202 +27,505	+22%	+$1.78M	﹤0.01%	1636
2022 Q3	$7.3M	Buy	123,697 +26,852	+28%	+$1.23M	﹤0.01%	2092
2022 Q2	$2.73M	Sell	96,845 -31,781	-25%	-$921K	﹤0.01%	2657
2022 Q1	$4.86M	Buy	128,626 +11,844	+10%	+$468K	﹤0.01%	2447
2021 Q4	$4.62M	Buy	116,782 +82,928	+245%	+$2.6M	﹤0.01%	2504
2021 Q3	$803K	Buy	33,854 +2,450	+8%	+$57.8K	﹤0.01%	3530
2021 Q2	$771K	Buy	+31,404	New	+$701K	﹤0.01%	3569

Other funds holding RXDX

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Bank of New York Mellon's RXDX Position: Q2 2023 in Review

Bank of New York Mellon sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 149,996 shares — an estimated $16.1M sold.

Bank of New York Mellon first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $16.6M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Bank of New York Mellon reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Bank of New York Mellon sold 149,996 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $16.1M.
Bank of New York Mellon first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Bank of New York Mellon's Prometheus Biosciences, Inc. Common Stock position peaked at $16.6M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Bank of New York Mellon's 13F filing for Q2 2023, filed 3 Aug 2023.